Saturday, July 13, 2024
Saturday, July 13, 2024
Home » Analysis: Wegovy Launch in UK May Underline Novo’s Need to Get Ahead of Lilly

Analysis: Wegovy Launch in UK May Underline Novo’s Need to Get Ahead of Lilly

by Kayden Collins
0 comment 63 views

Novo Nordisk’s decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly’s (LLY.N) own similar drug, industry sources said.

They said Novo may also have been responding to concerns voiced by the British government and patient advocacy groups over the off-label use for weight loss of its diabetes drug Ozempic, which contains the same active ingredient as Wegovy.

The Danish company has said it wants to get Wegovy to those most in need.

“Even though the launch is limited and controlled, we are doing our best to get access to Wegovy for people with obesity in the UK,” a Novo spokesperson said. “It is important that people with obesity have access to this medication and that our semaglutide products are used for their appropriate indication.”

Wegovy has helped Novo (NOVOb.CO) become Europe’s most valuable listed company, even though it has been unable to produce enough to meet demand in its existing markets. Before Monday’s British launch, the self-injection drug was already being sold in the United States, Norway, Denmark and Germany.

Based on obesity statistics and prescription criteria, several million Britons could potentially be eligible for Wegovy. A 2019 Organisation for Economic Co-operation and Development (OECD) report said nearly one in three adults are obese in Britain, the highest level in Europe.

CEO Lars Fruergaard Jorgensen told Reuters on Aug. 25 that while supplies are limited, Novo would “constrain” and “target” launches to ensure Wegovy reaches the neediest patients.

But some medical experts warned its decision to distribute Wegovy in Britain through private prescribers as well as the National Health Service (NHS) could stoke demand and mean people who can afford to pay themselves find it easier to access.

Novo has had to limit supplies of starter doses in the United States as demand gallops ahead of supply while German doctors also say stocks are low.

Three private companies now prescribing Wegovy in Britain told Reuters the amounts they had received last week from a wholesaler were a small fraction of the demand they had registered from potential patients.

The figures they gave Reuters suggested deliveries of several thousand per provider, while the NHS has repeatedly declined to comment this week on volumes it has received.

Novo said on Monday that it would allocate a portion of available supply to the NHS, which said at present around 50,000 patients could be eligible in England.

Source : Reuters

You may also like

Yew Media is a global leader in the online news. We seek to inform and engage with our readers. Staffed 24 hours, seven days a week by a dedicated team around the globe, we deliver news from journalists around the world. We are contrarian truth-seekers and truthtellers. We are journalists united by a mission to inform and engage with our readers. We bear witness to history as it unfolds and explain not just what happened, why it happened and what it means to our readers and the public. We are contrarian, we are committed to the news, speaking truth to power.

Yew Media, A Media Company – All Right Reserved.